2012 Hot Markets : Printing in a Mobile World

At No. 2 will be MEDICAL/PHARMACEUTICALS ($450B, +4 percent; with $13.5B to print, -3 percent), though less print will be dispensed. Generics will out-scrip proprietary drugs in the pharma/wellness space where the Teva/Proctor & Gamble joint venture will skin the game for packaging, ROP and POS. Biotechnology will be the only big print prescriber as major anti-aging breakthroughs hit the baby-boom marketplace from the likes of Allergan (+18 percent).